NVS up +1.03% percent Today $NVS High is at 95.47
Post# of 54
Posted On: 11/18/2014 1:41:58 PM
NVS up +1.03% percent Today $NVS High is at 95.47 and the Low 94.97 with current volume of 300,117.
Recent News posted below.
Novartis Ag NVS other info.
http://investorshangout.com/Novartis-Ag-NVS-52134/
NVS Novartis Ag Recent Headline News
Product and Pipeline Analysis of the Global Vaccines Market : Expected Launches in the Areas of Cancer and Allergies Will Drive Growth
PR Newswire - 1 hr 38 mins ago
Executive Summary
MRK: 59.96 (+0.50), GSK: 46.12 (+0.24), NVS: 95.53 (+1.15)
Redbooth Raises $11M Series B and Signs OEM Deal for CA Technologies to License Its Real-Time Enterprise Collaboration Platform
PR Newswire - 2 hrs 38 mins ago
Redbooth, the enterprise real-time collaboration software company, today announced it has secured an $11 million Series B round, bringing total funding to $17.5 million. Investment was led by Menlo Park-based VC firm Altpoint Ventures, and Boston-based Avalon Ventures. Redbooth has gained significant traction with enterprise customers, including GE, Avis, US Airways, Dell, Warner Bros., Novartis, and more who seek the benefits of a single, integrated platform offering all applications required for teams to get work done. This includes a recent release of Redbooth enterprise chat which has contributed to a 6x increase in user engagement since its launch last month.
NVS: 95.53 (+1.15)
Cancer Diagnostics (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) Market 2014 - 2020
M2 - Tue Nov 18, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/cgz62c/cancer) has announced the addition of the "Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Imaging, endoscopy, biopsy and tumor biomarker tests altogether comprise the global cancer diagnostics market. Imaging for cancer detection remains the largest segment in the cancer diagnostics market owing to its utilization in detection of almost every cancer type. MRI, PET, CT, mammography and ultrasound are the major imaging modalities, of which, CT scan and ultrasound imaging account for more than two-third of the total cancer imaging market. A tumor biomarker test is a segment in the cancer diagnostics market with highest research activity. Cancer biomarkers are increasingly being applied in cancer diagnostics; a highly sensitive and specific biomarker essentially helps in better diagnosis, monitoring and prognosis of cancer. Protein-based biomarkers such as alpha-fetoprotein (AFP), cancer embryonic antigen (CEA), prostate-specific antigen (PSA) are among the prominently used tumor biomarkers. The market for cancer diagnostics is majorly driven by demand from the patients affected with cancers of lung, breast, and colorectal cancer. Lung cancer is the most common cancer of all types and approximately 1.8 billion new cases of lung cancer were diagnosed in 2012. The increasing use of tobacco products in developing nations, particularly in BRICS countries, is contributing to the growing prevalence of lung cancer in the world. In 2013, the global lung cancer diagnostics market accounted for one-fourth of the global cancer diagnostics market revenue. In addition, the rising prevalence of breast cancer among women across the world, particularly in the Asia Pacific, is expected to drive the market for breast cancer diagnostics at the highest CAGR of 8.2% during the forecast period 2014 to 2020. The global cancer diagnostics market is led by players such as Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Eli Lilly and Co., Roche, GlaxoSmithKline plc, Novartis, and Pfizer. Scope of the Report Tumor Biomarker Tests: - PSA Tests - CTC Tests - AFP Tests - CA 19-9 - CA 125 - EGFR - HER2 - CEA - BRCA - KRAS - ALK Imaging - MRI Scan - PET Scan - CT Scan - Mammography - Ultrasound Endoscopy - Bronchoscopy - Colonoscopy - Sigmoidoscopy - Colposcopy - Others Biopsy - Bone Marrow Biopsy - Needle Biopsy - Endoscopic Biopsy Cancer Diagnostics Market, by Application: - Leukemia - Breast Cancer - Colorectal Cancer - Kidney - Liver - Lung - Ovarian - Pancreatic - Prostate Companies Mentioned - Abbott Laboratories, Inc. - Ambry Genetics - AstraZeneca plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genoptix, Inc. - GlaxoSmithKline plc - Pfizer, Inc. - bioMeriux SA For more information visit http://www.researchandmarkets.com/research/cgz62c/cancer
ABT: 43.75 (+0.04), PFE: 30.65 (+0.33), AZN: 73.78 (+1.28), LLY: 67.85 (+0.56), GSK: 46.12 (+0.24), NVS: 95.53 (+1.15)
Global miRNA Research and Diagnostics Markets Report 2014
M2 - Tue Nov 18, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjgcv3/mirna_research) has announced the addition of the "miRNA Research and Diagnostics Markets" report to their offering. This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that donot produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, alarge number of companies, both small biotechs and big pharmaceutical companiesare committed to miRNA diagnostics. As part of its coverage of this topic, this report includes the following: - Overview of miRNAs - Positive Factors for miRNA Diagnostic Technologies - Negative Factors - miRNAs and Neurological Disorders - miRNA and Metastatic Brain Lesions - Prostate Cancer Screening and miRNAs - miRNAs and Resistance to Anti-Cancer Drugs - Theoretical Limitations - Discussion of Patent Issues - Interviews with Industry Experts - Market Estimate As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail: - Agilent Technologies - AMSBIO - Applied Biosystems - DiamiR, LLC - Dicerna - Eisai Biomarkers and Personalized Medicine - Diagnostics - Genomic Health Inc. - Gensignia - GlaxoSmithKline Discovery and Molecular Toxicology - Groove Biopharma (formerly Mirina) - Hologic-Gen Probe Inc. - Illumina, Inc. - Isis Pharmaceuticals - Mello Biotechnology Inc. - Microlin Bio - MiRagen Therapeutics - MiRNA Therapeutics - Novartis - Pacific Edge Biotechnology - Prolias Technologies - Regulus Therapeutics - Rosetta Genomics - Santaris Pharma A/S - Sirnaomics, Inc. - Somagenics - Diagnostics: Small RNA Assays and Biomarker Validation - Tekmira Pharmaceuticals Corporation - Thermadiag - Thermo Fisher Scientific, Inc. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Current State of the Art 4. Companies Developing microRNA Diagnostic Technologies 5. Market Estimates and Forecasts 6. Interviews with Industry Experts: Biomarkers 7. The Future of miRNA-Based Diagnostics For more information visit http://www.researchandmarkets.com/research/fj...a_research
ISIS: 49.95 (+0.94), A: 40.79 (-0.45), TKMR: 16.60 (-0.64), ILMN: 191.58 (+8.67), RGLS: 18.47 (+1.62), GSK: 46.12 (+0.24), HOLX: 26.74 (+0.37), GHDX: 32.49 (+0.81), NVS: 95.53 (+1.15)
PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy
M2 - Tue Nov 18, 9:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/f3mqsf/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy" report to their offering. "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy", provides strategic analysis of the global stem cells industry. It discusses key development trends, regulatory requirements in various markets, recent deals activity and industry dynamic trends, as well as describes the operations strategy of these companies. Analyze and track the strategies that companies are using to enter and/or strengthen their position in the evolving stem cell industry, as well as efforts being made by innovator companies like Pfizer and Novartis to enter this market. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as China, India, SouthKorea, and Israel-providing in-depth analysis of these markets' regulatory framework, key domestic players and their stem cell pipelines, and strategic outlook. Throughout the report, Our analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions. Key Questions Answered - What are the key market drivers of the global stem cell industry? - Who are the top players involved in the development of stem cell therapies in developed as well as developing countries? - What are the main regulatory measures affecting the stem cell industry in the US, Europe, Japan, India, South Korea, China and Israel? - What are the major trends in stem cell clinical trials and profiles of key investigators? - What specific strategies are companies utilizing to combat some of the challenges currently facing the development of therapies in the global stem cell industry? Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Stem Cell Overview 4 Stem Cell Pipeline 5 Stem Cell Clinical Trials 6 Stem Cell Deals 7 Stem Cell Regulation 8 Company Landscape 9 Strategic Outlook 10 Appendix Companies Mentioned - Advanced Cell Technology - Anterogen - Asterias Biotherapeutics - Athersys - Bioheart - Bone Therapeutics - BrainStorm Cell Therapeutics - CHA Bio & Diostech - California Stem Cell - Capricor Therapeutics - Cardio3 BioSciences - Celgene - Cell Cure Neurosciences - Cellerant Therapeutics - Cellular Biomedicine Group - Cytomedix - Escape Therapeutics - Fate Therapeutics - Gamida Cell - Histocell - Orbsen Therapeutics - Pharmicell - Pluristem - Promethera Biosciences - ReNeuron - Reliance Life Sciences - Shenzhen Beike Biotechnology - StemCells - Stemedica - Stempeutics For more information visit http://www.researchandmarkets.com/research/f3...armasphere
FATE: 4.00 (+0.25), AST: 3.74 (-0.12), CBMG: 16.00 (+0.20), BCLI: 3.38 (unch), NVS: 95.53 (+1.15), CELGZ: 3.10 (-0.11)
Global Peanut Allergy Clinical Trials Review 2014 - Analysis of Top 7 Companies & 10 Institutues
M2 - Tue Nov 18, 8:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/qz9gnl/peanut_allergy) has announced the addition of the "Peanut Allergy Global Clinical Trials Review, H2, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Peanut Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Peanut Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - DBV Technologies SA - F. Hoffmann-La Roche Ltd. - Novartis AG - Allergen Research Corporation - Immunomic Therapeutics, Inc. - HAL Allergy BV - Allertein Therapeutics, LLC Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - The University of North Carolina at Chapel Hill - University of North Carolina - Johns Hopkins University - Massachusetts General Hospital - Boston Children's Hospital - Baylor College of Medicine - McMaster University - Hamilton Health Sciences - Karolinska Institute For more information visit http://www.researchandmarkets.com/research/qz...ut_allergy
DBVT: 24.75 (+0.21), NVS: 95.53 (+1.15)
Novartis presents new data on heart failure drug candidate
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 6:47AM CST
NVS: 95.53 (+1.15)
Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology
Business Wire - Tue Nov 18, 6:00AM CST
Intellia Therapeutics, a new company formed to develop therapeutic products using CRISPR-Cas9 technology for gene editing and repair, announced today that it has closed a Series A investment round with $15 million in financing led by Atlas Venture and Novartis. Created by Atlas Venture and Caribou Biosciences, together with leading scientists who have pioneered and shaped the field of CRISPR biology, Intellia leverages exclusive access to one of the most comprehensive intellectual property portfolios covering the therapeutic application of this transformative technology.
NVS: 95.53 (+1.15)
Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually
PR Newswire - Tue Nov 18, 6:00AM CST
A new global survey of more than 10,000 adults in 10 countries finds that a large majority of the general public feel they know little or nothing about lung cancer (84%), a devastating disease that is responsible for 1.59 million deaths annually, more than breast, colorectal and prostate cancers combined1,2,4. The "Any One Any Lung" survey uncovered not only a significant lack of understanding about the widespread impact of lung cancer, but also a critical absence of knowledge around the role of genetic changes in the development of the disease1. These knowledge gaps and misperceptions may lead to undue blame placed on the patient, negatively affecting those impacted by lung cancer and in need of support.
NVS: 95.53 (+1.15)
Will IPOs WhiteWave, Enanta Surpass Buy Points?
at Investor's Business Daily - Mon Nov 17, 5:27PM CST
With the market in a confirmed uptrend, many IPO Leaders are extended beyond their buy points. But a few, including WhiteWave Foods (WWAV) and Enanta Pharmaceuticals (ENTA), are still within striking distance. WhiteWave has been trading near a 37.25...
WWAV: 36.98 (+0.45), ABBV: 66.00 (+0.96), ENTA: 43.68 (-0.29), NVS: 95.53 (+1.15)
Sanofi's Lemtrada Gets U.S. Approval, Carries Boxed Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 4:20PM CST
Sanofi's (SNY) Lemtrada has finally gained FDA approval for the treatment of patients suffering from relapsing forms of MS.
BIIB: 305.37 (+2.95), SNY: 48.44 (+0.90), NVS: 95.53 (+1.15)
Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients
PR Newswire - Mon Nov 17, 3:47PM CST
New data on Novartis' investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction (HFrEF) shows it has the potential to change the course of the disease for patients.1,2 In August 2014, Novartis presented topline results from the landmark PARADIGM-HF study showing LCZ696 was superior to ACE inhibitor enalapril on key endpoints, including significantly reducing the risk of cardiovascular (CV) death or heart failure hospitalization.5
NVS: 95.53 (+1.15)
Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients[1],[2]
Thomson Reuters ONE - Mon Nov 17, 3:45PM CST
Novartis International AG / Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients[1],[2] . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 95.53 (+1.15)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.98 (+0.68), GILD: 103.40 (+2.96), GERN: 3.15 (+0.17), MRK: 59.96 (+0.50), AZN: 73.78 (+1.28), PFE: 30.65 (+0.33), INCY: 69.24 (-0.46), BMY: 58.68 (+0.25), CTIC: 2.27 (+0.03), NVS: 95.53 (+1.15)
Jim Cramer Answers Twitter (TWTR) Questions on Gold, Gilead and More
at The Street - Mon Nov 17, 1:53PM CST
TheStreet's Jim Cramer answers Twitter (TWTR) questions on gold, Gilead (GILD), energy stocks and more.
JNJ: 108.98 (+0.68), GILD: 103.39 (+2.95), GLD: 115.16 (+1.11), ABBV: 66.00 (+0.96), TWTR: 40.66 (+0.19), NVS: 95.53 (+1.15)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Novartis Is Up 1.7% (NVS)
Comtex SmarTrend(R) - Mon Nov 17, 12:17PM CST
Two weeks ago on October 28th, 2014 Novartis (NYSE:NVS) reported earnings and analysts, on average, expected earnings of $1.30 on sales of $14.5 billion. The company actually reported a break-even quarter on sales of $13.0 billion, missing EPS estimates by $1.30 and missing revenue estimates by $14,504.5 billion. Since the company's report, shares of Novartis have risen from $92.35 to $93.95, representing a gain of 1.7% in the past 20 days.
NVS: 95.53 (+1.15)
How to Pick Stocks in the Wake of the Republican Election Victory
at The Street - Mon Nov 17, 11:42AM CST
From Keystone to pharmaceuticals, industrials and energy, the Republican wins in midterm elections create real opportunities investors can take advantage of.
PFE: 30.65 (+0.33), GSK: 46.12 (+0.24), CAT: 102.04 (+0.34), BA: 130.43 (+2.01), NVS: 95.53 (+1.15)
Novartis presents results from four pivotal Phase III studies for investigational drug secukinumab (AIN457) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
CNW Group - Mon Nov 17, 7:00AM CST
Novartis presented first-time results of four pivotal phase III studies evaluating the interleukin-17A (IL-17A) inhibitor investigational secukinumab (AIN457) in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) at the American College of Rheumatology (ACR) Annual Meeting, 14-19 November, in Boston, USA.
NVS: 95.53 (+1.15)
Novartis first IL-17A Phase III results show AIN457 (secukinumab) significantly improves psoriatic arthritis in patients
PR Newswire - Sun Nov 16, 1:37PM CST
Novartis announced today results from the pivotal Phase III FUTURE 1 and FUTURE 2 studies showing AIN457 (secukinumab) met primary endpoints demonstrating statistically significant improvement of the signs and symptoms of psoriatic arthritis (PsA) versus placebo. PsA is part of a spectrum of long-term diseases impacting joints, known as spondyloarthritis (SpA). There is a high unmet need for new treatment options for patients with PsA and approximately 45% of people are dissatisfied with their treatments. Secukinumab binds to and neutralizes interleukin-17A (IL-17A), which has been shown to play an important role in the development of inflammatory diseases. These results are being presented today at the American College of Rheumatology (ACR) Annual Meeting in Boston.
NVS: 95.53 (+1.15)
Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients
Thomson Reuters ONE - Sun Nov 16, 1:31PM CST
Novartis International AG / Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 95.53 (+1.15)
Recent News posted below.
Novartis Ag NVS other info.
http://investorshangout.com/Novartis-Ag-NVS-52134/
NVS Novartis Ag Recent Headline News
Product and Pipeline Analysis of the Global Vaccines Market : Expected Launches in the Areas of Cancer and Allergies Will Drive Growth
PR Newswire - 1 hr 38 mins ago
Executive Summary
MRK: 59.96 (+0.50), GSK: 46.12 (+0.24), NVS: 95.53 (+1.15)
Redbooth Raises $11M Series B and Signs OEM Deal for CA Technologies to License Its Real-Time Enterprise Collaboration Platform
PR Newswire - 2 hrs 38 mins ago
Redbooth, the enterprise real-time collaboration software company, today announced it has secured an $11 million Series B round, bringing total funding to $17.5 million. Investment was led by Menlo Park-based VC firm Altpoint Ventures, and Boston-based Avalon Ventures. Redbooth has gained significant traction with enterprise customers, including GE, Avis, US Airways, Dell, Warner Bros., Novartis, and more who seek the benefits of a single, integrated platform offering all applications required for teams to get work done. This includes a recent release of Redbooth enterprise chat which has contributed to a 6x increase in user engagement since its launch last month.
NVS: 95.53 (+1.15)
Cancer Diagnostics (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) Market 2014 - 2020
M2 - Tue Nov 18, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/cgz62c/cancer) has announced the addition of the "Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Imaging, endoscopy, biopsy and tumor biomarker tests altogether comprise the global cancer diagnostics market. Imaging for cancer detection remains the largest segment in the cancer diagnostics market owing to its utilization in detection of almost every cancer type. MRI, PET, CT, mammography and ultrasound are the major imaging modalities, of which, CT scan and ultrasound imaging account for more than two-third of the total cancer imaging market. A tumor biomarker test is a segment in the cancer diagnostics market with highest research activity. Cancer biomarkers are increasingly being applied in cancer diagnostics; a highly sensitive and specific biomarker essentially helps in better diagnosis, monitoring and prognosis of cancer. Protein-based biomarkers such as alpha-fetoprotein (AFP), cancer embryonic antigen (CEA), prostate-specific antigen (PSA) are among the prominently used tumor biomarkers. The market for cancer diagnostics is majorly driven by demand from the patients affected with cancers of lung, breast, and colorectal cancer. Lung cancer is the most common cancer of all types and approximately 1.8 billion new cases of lung cancer were diagnosed in 2012. The increasing use of tobacco products in developing nations, particularly in BRICS countries, is contributing to the growing prevalence of lung cancer in the world. In 2013, the global lung cancer diagnostics market accounted for one-fourth of the global cancer diagnostics market revenue. In addition, the rising prevalence of breast cancer among women across the world, particularly in the Asia Pacific, is expected to drive the market for breast cancer diagnostics at the highest CAGR of 8.2% during the forecast period 2014 to 2020. The global cancer diagnostics market is led by players such as Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Eli Lilly and Co., Roche, GlaxoSmithKline plc, Novartis, and Pfizer. Scope of the Report Tumor Biomarker Tests: - PSA Tests - CTC Tests - AFP Tests - CA 19-9 - CA 125 - EGFR - HER2 - CEA - BRCA - KRAS - ALK Imaging - MRI Scan - PET Scan - CT Scan - Mammography - Ultrasound Endoscopy - Bronchoscopy - Colonoscopy - Sigmoidoscopy - Colposcopy - Others Biopsy - Bone Marrow Biopsy - Needle Biopsy - Endoscopic Biopsy Cancer Diagnostics Market, by Application: - Leukemia - Breast Cancer - Colorectal Cancer - Kidney - Liver - Lung - Ovarian - Pancreatic - Prostate Companies Mentioned - Abbott Laboratories, Inc. - Ambry Genetics - AstraZeneca plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genoptix, Inc. - GlaxoSmithKline plc - Pfizer, Inc. - bioMeriux SA For more information visit http://www.researchandmarkets.com/research/cgz62c/cancer
ABT: 43.75 (+0.04), PFE: 30.65 (+0.33), AZN: 73.78 (+1.28), LLY: 67.85 (+0.56), GSK: 46.12 (+0.24), NVS: 95.53 (+1.15)
Global miRNA Research and Diagnostics Markets Report 2014
M2 - Tue Nov 18, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjgcv3/mirna_research) has announced the addition of the "miRNA Research and Diagnostics Markets" report to their offering. This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that donot produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, alarge number of companies, both small biotechs and big pharmaceutical companiesare committed to miRNA diagnostics. As part of its coverage of this topic, this report includes the following: - Overview of miRNAs - Positive Factors for miRNA Diagnostic Technologies - Negative Factors - miRNAs and Neurological Disorders - miRNA and Metastatic Brain Lesions - Prostate Cancer Screening and miRNAs - miRNAs and Resistance to Anti-Cancer Drugs - Theoretical Limitations - Discussion of Patent Issues - Interviews with Industry Experts - Market Estimate As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail: - Agilent Technologies - AMSBIO - Applied Biosystems - DiamiR, LLC - Dicerna - Eisai Biomarkers and Personalized Medicine - Diagnostics - Genomic Health Inc. - Gensignia - GlaxoSmithKline Discovery and Molecular Toxicology - Groove Biopharma (formerly Mirina) - Hologic-Gen Probe Inc. - Illumina, Inc. - Isis Pharmaceuticals - Mello Biotechnology Inc. - Microlin Bio - MiRagen Therapeutics - MiRNA Therapeutics - Novartis - Pacific Edge Biotechnology - Prolias Technologies - Regulus Therapeutics - Rosetta Genomics - Santaris Pharma A/S - Sirnaomics, Inc. - Somagenics - Diagnostics: Small RNA Assays and Biomarker Validation - Tekmira Pharmaceuticals Corporation - Thermadiag - Thermo Fisher Scientific, Inc. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Current State of the Art 4. Companies Developing microRNA Diagnostic Technologies 5. Market Estimates and Forecasts 6. Interviews with Industry Experts: Biomarkers 7. The Future of miRNA-Based Diagnostics For more information visit http://www.researchandmarkets.com/research/fj...a_research
ISIS: 49.95 (+0.94), A: 40.79 (-0.45), TKMR: 16.60 (-0.64), ILMN: 191.58 (+8.67), RGLS: 18.47 (+1.62), GSK: 46.12 (+0.24), HOLX: 26.74 (+0.37), GHDX: 32.49 (+0.81), NVS: 95.53 (+1.15)
PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy
M2 - Tue Nov 18, 9:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/f3mqsf/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy" report to their offering. "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy", provides strategic analysis of the global stem cells industry. It discusses key development trends, regulatory requirements in various markets, recent deals activity and industry dynamic trends, as well as describes the operations strategy of these companies. Analyze and track the strategies that companies are using to enter and/or strengthen their position in the evolving stem cell industry, as well as efforts being made by innovator companies like Pfizer and Novartis to enter this market. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as China, India, SouthKorea, and Israel-providing in-depth analysis of these markets' regulatory framework, key domestic players and their stem cell pipelines, and strategic outlook. Throughout the report, Our analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions. Key Questions Answered - What are the key market drivers of the global stem cell industry? - Who are the top players involved in the development of stem cell therapies in developed as well as developing countries? - What are the main regulatory measures affecting the stem cell industry in the US, Europe, Japan, India, South Korea, China and Israel? - What are the major trends in stem cell clinical trials and profiles of key investigators? - What specific strategies are companies utilizing to combat some of the challenges currently facing the development of therapies in the global stem cell industry? Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Stem Cell Overview 4 Stem Cell Pipeline 5 Stem Cell Clinical Trials 6 Stem Cell Deals 7 Stem Cell Regulation 8 Company Landscape 9 Strategic Outlook 10 Appendix Companies Mentioned - Advanced Cell Technology - Anterogen - Asterias Biotherapeutics - Athersys - Bioheart - Bone Therapeutics - BrainStorm Cell Therapeutics - CHA Bio & Diostech - California Stem Cell - Capricor Therapeutics - Cardio3 BioSciences - Celgene - Cell Cure Neurosciences - Cellerant Therapeutics - Cellular Biomedicine Group - Cytomedix - Escape Therapeutics - Fate Therapeutics - Gamida Cell - Histocell - Orbsen Therapeutics - Pharmicell - Pluristem - Promethera Biosciences - ReNeuron - Reliance Life Sciences - Shenzhen Beike Biotechnology - StemCells - Stemedica - Stempeutics For more information visit http://www.researchandmarkets.com/research/f3...armasphere
FATE: 4.00 (+0.25), AST: 3.74 (-0.12), CBMG: 16.00 (+0.20), BCLI: 3.38 (unch), NVS: 95.53 (+1.15), CELGZ: 3.10 (-0.11)
Global Peanut Allergy Clinical Trials Review 2014 - Analysis of Top 7 Companies & 10 Institutues
M2 - Tue Nov 18, 8:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/qz9gnl/peanut_allergy) has announced the addition of the "Peanut Allergy Global Clinical Trials Review, H2, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Peanut Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Peanut Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - DBV Technologies SA - F. Hoffmann-La Roche Ltd. - Novartis AG - Allergen Research Corporation - Immunomic Therapeutics, Inc. - HAL Allergy BV - Allertein Therapeutics, LLC Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - The University of North Carolina at Chapel Hill - University of North Carolina - Johns Hopkins University - Massachusetts General Hospital - Boston Children's Hospital - Baylor College of Medicine - McMaster University - Hamilton Health Sciences - Karolinska Institute For more information visit http://www.researchandmarkets.com/research/qz...ut_allergy
DBVT: 24.75 (+0.21), NVS: 95.53 (+1.15)
Novartis presents new data on heart failure drug candidate
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 6:47AM CST
NVS: 95.53 (+1.15)
Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology
Business Wire - Tue Nov 18, 6:00AM CST
Intellia Therapeutics, a new company formed to develop therapeutic products using CRISPR-Cas9 technology for gene editing and repair, announced today that it has closed a Series A investment round with $15 million in financing led by Atlas Venture and Novartis. Created by Atlas Venture and Caribou Biosciences, together with leading scientists who have pioneered and shaped the field of CRISPR biology, Intellia leverages exclusive access to one of the most comprehensive intellectual property portfolios covering the therapeutic application of this transformative technology.
NVS: 95.53 (+1.15)
Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually
PR Newswire - Tue Nov 18, 6:00AM CST
A new global survey of more than 10,000 adults in 10 countries finds that a large majority of the general public feel they know little or nothing about lung cancer (84%), a devastating disease that is responsible for 1.59 million deaths annually, more than breast, colorectal and prostate cancers combined1,2,4. The "Any One Any Lung" survey uncovered not only a significant lack of understanding about the widespread impact of lung cancer, but also a critical absence of knowledge around the role of genetic changes in the development of the disease1. These knowledge gaps and misperceptions may lead to undue blame placed on the patient, negatively affecting those impacted by lung cancer and in need of support.
NVS: 95.53 (+1.15)
Will IPOs WhiteWave, Enanta Surpass Buy Points?
at Investor's Business Daily - Mon Nov 17, 5:27PM CST
With the market in a confirmed uptrend, many IPO Leaders are extended beyond their buy points. But a few, including WhiteWave Foods (WWAV) and Enanta Pharmaceuticals (ENTA), are still within striking distance. WhiteWave has been trading near a 37.25...
WWAV: 36.98 (+0.45), ABBV: 66.00 (+0.96), ENTA: 43.68 (-0.29), NVS: 95.53 (+1.15)
Sanofi's Lemtrada Gets U.S. Approval, Carries Boxed Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 4:20PM CST
Sanofi's (SNY) Lemtrada has finally gained FDA approval for the treatment of patients suffering from relapsing forms of MS.
BIIB: 305.37 (+2.95), SNY: 48.44 (+0.90), NVS: 95.53 (+1.15)
Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients
PR Newswire - Mon Nov 17, 3:47PM CST
New data on Novartis' investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction (HFrEF) shows it has the potential to change the course of the disease for patients.1,2 In August 2014, Novartis presented topline results from the landmark PARADIGM-HF study showing LCZ696 was superior to ACE inhibitor enalapril on key endpoints, including significantly reducing the risk of cardiovascular (CV) death or heart failure hospitalization.5
NVS: 95.53 (+1.15)
Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients[1],[2]
Thomson Reuters ONE - Mon Nov 17, 3:45PM CST
Novartis International AG / Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients[1],[2] . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 95.53 (+1.15)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.98 (+0.68), GILD: 103.40 (+2.96), GERN: 3.15 (+0.17), MRK: 59.96 (+0.50), AZN: 73.78 (+1.28), PFE: 30.65 (+0.33), INCY: 69.24 (-0.46), BMY: 58.68 (+0.25), CTIC: 2.27 (+0.03), NVS: 95.53 (+1.15)
Jim Cramer Answers Twitter (TWTR) Questions on Gold, Gilead and More
at The Street - Mon Nov 17, 1:53PM CST
TheStreet's Jim Cramer answers Twitter (TWTR) questions on gold, Gilead (GILD), energy stocks and more.
JNJ: 108.98 (+0.68), GILD: 103.39 (+2.95), GLD: 115.16 (+1.11), ABBV: 66.00 (+0.96), TWTR: 40.66 (+0.19), NVS: 95.53 (+1.15)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Novartis Is Up 1.7% (NVS)
Comtex SmarTrend(R) - Mon Nov 17, 12:17PM CST
Two weeks ago on October 28th, 2014 Novartis (NYSE:NVS) reported earnings and analysts, on average, expected earnings of $1.30 on sales of $14.5 billion. The company actually reported a break-even quarter on sales of $13.0 billion, missing EPS estimates by $1.30 and missing revenue estimates by $14,504.5 billion. Since the company's report, shares of Novartis have risen from $92.35 to $93.95, representing a gain of 1.7% in the past 20 days.
NVS: 95.53 (+1.15)
How to Pick Stocks in the Wake of the Republican Election Victory
at The Street - Mon Nov 17, 11:42AM CST
From Keystone to pharmaceuticals, industrials and energy, the Republican wins in midterm elections create real opportunities investors can take advantage of.
PFE: 30.65 (+0.33), GSK: 46.12 (+0.24), CAT: 102.04 (+0.34), BA: 130.43 (+2.01), NVS: 95.53 (+1.15)
Novartis presents results from four pivotal Phase III studies for investigational drug secukinumab (AIN457) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
CNW Group - Mon Nov 17, 7:00AM CST
Novartis presented first-time results of four pivotal phase III studies evaluating the interleukin-17A (IL-17A) inhibitor investigational secukinumab (AIN457) in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) at the American College of Rheumatology (ACR) Annual Meeting, 14-19 November, in Boston, USA.
NVS: 95.53 (+1.15)
Novartis first IL-17A Phase III results show AIN457 (secukinumab) significantly improves psoriatic arthritis in patients
PR Newswire - Sun Nov 16, 1:37PM CST
Novartis announced today results from the pivotal Phase III FUTURE 1 and FUTURE 2 studies showing AIN457 (secukinumab) met primary endpoints demonstrating statistically significant improvement of the signs and symptoms of psoriatic arthritis (PsA) versus placebo. PsA is part of a spectrum of long-term diseases impacting joints, known as spondyloarthritis (SpA). There is a high unmet need for new treatment options for patients with PsA and approximately 45% of people are dissatisfied with their treatments. Secukinumab binds to and neutralizes interleukin-17A (IL-17A), which has been shown to play an important role in the development of inflammatory diseases. These results are being presented today at the American College of Rheumatology (ACR) Annual Meeting in Boston.
NVS: 95.53 (+1.15)
Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients
Thomson Reuters ONE - Sun Nov 16, 1:31PM CST
Novartis International AG / Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 95.53 (+1.15)
(0)
(0)Novartis Ag (NVS) Stock Research Links
Scroll down for more posts ▼